Introduction
============

Approximately 60% of breast cancers in premenopausal women reportedly express the estrogen receptor (ER) and/or the progesterone receptor (PR) \[[@b1-crt-2015-444]\]; the actual prevalence rates in Korea are 69.9% and 58.3%, respectively \[[@b2-crt-2015-444]\]. The goal of adjuvant hormonal therapy in hormone-responsive breast cancer patients is to reduce the availability of estrogen to cancer cells, which can be achieved by blocking ERs with drugs such as tamoxifen, suppressing estrogen synthesis using a gonadotropin-releasing hormone (GnRH) agonist, or surgical/radiological removal of ovaries. Among these treatments, the role and efficacy of ovarian suppression with a GnRH agonist remains to be fully defined. Based on the recently published results of the Suppression of Ovarian Function Trial (SOFT), it was concluded that addition of ovarian suppression to tamoxifen does not provide significant benefit in premenopausal patients with breast cancer. However, the addition of ovarian suppression improves disease outcomes in women who remain premenopausal after chemotherapy \[[@b3-crt-2015-444]\]. On the other hand, several trials have shown that ovarian suppression or ablation can exert effects similar to that of chemotherapy in the treatment of ER-positive breast cancer in premenopausal women \[[@b4-crt-2015-444]-[@b7-crt-2015-444]\]. In addition, because it is widely documented that patients treated with a GnRH agonist alone showed a better quality of life than patients treated with chemotherapy, a few studies have evaluated GnRH agonists as substitutes for chemotherapy in hormone-responsive breast cancer patients \[[@b8-crt-2015-444]-[@b12-crt-2015-444]\]. In their 7-year follow-up of the French Adjuvant Study Group 06 randomized trial, Roche et al. \[[@b13-crt-2015-444]\] reported that combining GnRH agonist and tamoxifen (GnRHa+T) and epirubicin-based chemotherapy without hormonal therapy showed similar 7-year disease-free survival and overall survival (OS) rates in premenopausal patients with N1, early breast cancer. Similarly, Kim et al. \[[@b14-crt-2015-444]\] concluded that GnRHa+T can be an alternative treatment option to sequential adriamycin and cyclophosphamide (AC) chemotherapy and tamoxifen (AC-\>T) in premenopausal patients with hormone receptor-positive, hormone-responsive, lymph-node--negative (N0) breast cancer.

The primary aim of this retrospective study was to compare survival outcomes in premenopausal patients with T1-T2, hormone-responsive, HER2-negative breast cancer between GnRHa+T for 2 years and AC-\>T.

Materials and Methods
=====================

1. Study design
---------------

Between January 2003 and December 2008, 7,278 patients were diagnosed with and registered as having breast cancer at Asan Medical Center, Seoul, Korea; 2,085 patients had T1-T2, N0, hormone-responsive, HER2-negative breast cancer, and 1,468 were premenopausal. GnRHa+T and AC-\>T were administered to 608 and 386 patients, respectively, as a postoperative adjuvant breast cancer treatment; therefore, 994 patients were included in the final analysis ([Fig. 1](#f1-crt-2015-444){ref-type="fig"}). Premenopausal status was confirmed in those who had menstruated less than 1 year before surgery or had a premenopausal follicle-stimulating hormone level of less than 30 IU/mL. Premenopausal patients with T1-T2, N0, M0, hormone-responsive, HER2-negative breast cancer were provided with complete information about the efficacies and benefits of GnRHa+T and AC-\>T, and each patient then chose her preferred regimen. Patients in the AC-\>T group received four cycles of AC chemotherapy (60 mg/m^2^ adriamycin intravenously plus 60 mg/m^2^ cyclophosphamide intravenously every 21 days) followed by tamoxifen (20 mg/day for 5 years or until relapse or intolerance). Patients in the GnRHa+T group received GnRH agonist (3.6 mg/kg goserelin or 3.75 mg/kg leuprorelin) for 2 years and tamoxifen simultaneously for 5 years.

The concentrations of hormone receptors in formalin-fixed, paraffin-embedded tissue sections of the primary tumors were determined using primary antibodies against ER (1:50, Dinona, Seoul, Korea) and PR (1:100, Dinona) in a Benchmark automatic immunostaining device (Ventana Medical Systems, Tucson, AZ). Nuclear staining was scored as 0 (negative), 1-3 (weakly positive), 4 or 5 (intermediately positive), or 6 or 7 (strong positive), while hormone receptor positivity was defined as a score over 4. HER2 status was confirmed by immunohistochemistry, and HER2 receptor negativity was defined as negative, 1+ or 2+.

2. Statistical analysis
-----------------------

The recurrence-free survival (RFS) period was defined as the time from the operation to disease recurrence or death (whichever occurred first), the cancer-specific survival (CSS) period was defined as the time from the operation to cancer-caused death, and the OS period was defined as the time from the operation to death from any cause. Patient characteristics were compared between treatment groups using Pearson's chi-square test. RFS, CSS, and OS were assessed using Kaplan-Meier curves and compared using a log-rank test. The Cox proportional hazards (PH) model was used for calculation of the adjusted hazard ratios of the treatment effect while accounting for the effects of patient characteristics and other significant prognostic factors. Variables were assessed on a univariate basis, and factors with a significance probability of ≤ 0.25 were included in multivariate analysis and selected using backward elimination.

To reduce the effect of selection bias when assigning patients to either GnRHa+T or AC-\>T, a propensity score (PS)--based analysis was also performed to produce a rigorous adjustment of the baseline characteristics of the patients. PSs were estimated using multiple logistic regression analysis with all pre-specified covariates listed in [Table 1](#t1-crt-2015-444){ref-type="table"}. Model discrimination was assessed using *c*-statistics (*c*=0.773), and model calibration was performed using Hosmer-Lemeshow statistics (p=0.152). Both treatment groups were matched based on their estimated PSs, with caliper widths of 0.1. The balance of baseline covariates was checked by calculating the standardized difference of means. To account for the matched nature of subject selection, a Cox PH model was performed with a sandwich estimator of variance. A Cox PH model was also performed with inverse probability of treatment weighting, called an inverse probability--weighted Cox model, using the PS. The estimated hazards from several methods described above are reported. A probability value of p ≤ 0.05 indicated statistical significance. Results were analyzed using SPSS ver. 21 for Windows (IBM Co., Armonk, NY) and R 3.0.2 (free software which can be downloaded from <http://www.r-project.org>) with package 'MatchIt' and 'Survival.'

Results
=======

1. Patients and tumor characteristics
-------------------------------------

Of the 994 patients, 674 (67.8%) had T1, N0 disease and 320 (32.2%) had T2, N0 disease. Among the patients with T1 disease, 493 (73.2%) received GnRHa+T and 181 (26.8%) received AC-\>T. Among the patients with T2 disease, 115 (35.7%) received GnRHa+T and 205 (64.3%) received AC-\>T. Because this is a retrospective study, there is heterogeneity in the patients' age, tumor stage, ER positivity, PR positivity, and histologic and nuclear grade in the two treatment groups of the original cohort. We therefore applied PS matching, which produced 260 matched patients in each treatment arm ([Table 1](#t1-crt-2015-444){ref-type="table"}). In these matched cohorts, there were no significant group differences in age, operation method, nuclear and histologic grades, ER positivity, PR positivity, or tumor stage.

2. Survival analysis
--------------------

The 994 patients were followed up for a median of 7.4 years (range, 0.5 to 11.4 years). The 5-year follow-up rate was 98.7%, with 13 patients lost to follow-up: two patients were lost within 1 year after surgery and six patients within 3 years after surgery. The 5-year RFS rate was 95.9%; recurrence in 68 patients included 35 patients with loco-regional recurrence and 33 patients with distant metastasis. Among 35 loco-regional recurrences, 18 patients had in-breast recurrences, seven patients had axillary lymph node metastasis, four patients had supraclavicular lymph node metastasis, and six had internal mammary lymph node metastasis. The 5-year CSS and OS rates were 98.9% and 98.3%, respectively (14 cancer-specific and 25 overall deaths). RFS, CSS, and OS in overall cohort, T1a+T1b group, T1c group, T2 group, and propensity-matched cohorts are shown separately in [Table 2](#t2-crt-2015-444){ref-type="table"}. Considering different clinical characteristics between the two treatment groups showing smaller tumor size, low nuclear and histologic grade in the GnRHa+T group, it resulted in favorable CSS and OS for the GnRHa+T group in the overall cohort. However, in subgroup analysis based on tumor size, there was no difference in survival between the two treatment groups.

Of the 520 patients in the propensity-matched cohorts, 34 patients showed recurrence, with five cancer-specific deaths and 12 overall deaths. The survival rate did not differ significantly between the two treatment groups among these propensity-matched patients ([Table 2](#t2-crt-2015-444){ref-type="table"}). The Kaplan-Meier survival curves for the two treatment arms in the overall cohort, T1a+T1b group, T1c group, and T2 group are shown in [Fig. 2](#f2-crt-2015-444){ref-type="fig"}, and the Kaplan-Meier survival curves in propensity-matched cohorts are shown in [Fig. 3](#f3-crt-2015-444){ref-type="fig"}.

Propensity matching, inverse probability weighting was applied to the original cohort. Results of the Cox regression analysis of RFS, CSS, and OS with application of inverse probability of weighting are shown in [Table 3](#t3-crt-2015-444){ref-type="table"}. There were no group differences in RFS and CSS, but OS was significantly better in the GnRHa+T group (p=0.021). Kaplan-Meier estimates between the treatment arms in inverse-probability-weighted cohorts are shown in [Fig. 4](#f4-crt-2015-444){ref-type="fig"}.

Discussion
==========

The primary aim of this study was to compare treatment outcomes between GnRHa+T and AC-\>T in premenopausal patients with T1-T2, hormone-responsive, HER2-negative breast cancer. Similar to other studies comparing the efficacies of GnRH agonist and chemotherapy in premenopausal breast cancer patients \[[@b13-crt-2015-444],[@b14-crt-2015-444]\], our patients in the GnRHa+T group showed comparable treatment outcomes to those in the AC-\>T group.

The efficacy of ovarian suppression in premenopausal breast cancer has been addressed in several clinical trials. The Zoladex Early Bresat Cancer Research Association, ZEBRA) trial \[[@b6-crt-2015-444],[@b15-crt-2015-444]\] and International Breast Cancer Study Group (IBCSG) VIII \[[@b16-crt-2015-444]\] trials found similar efficacy for GnRH agonist and cyclophosphamide, methotrexate, 5-fluorouracil chemotherapy chemotherapy in terms of RFS and OS in hormone-responsive early breast cancer. Kim et al. \[[@b14-crt-2015-444]\] compared the efficacies of GnRHa+T and AC-\>T with a median follow-up period of 30 months. Although that was a small, preliminary study with a relatively short follow-up period, the authors concluded that GnRHa+T can be an alternative treatment option in premenopausal patients with endocrine-responsive, N0 breast cancer. In their 7-year follow-up of the French Adjuvant Study Group 06 randomized trial, Roche et al. \[[@b13-crt-2015-444]\] reported similar 7-year RFS and OS rates in premenopausal patients with N1, early breast cancer for GnRHa+T and epirubicin-based chemotherapy. On the other hand, based on SOFT data \[[@b3-crt-2015-444]\], it was concluded that addition of ovarian suppression to tamoxifen did not provide a significant benefit in the overall population of premenopausal women. However, those authors also stated that in the cohort of women whose risk of recurrence was sufficient to warrant adjuvant chemotherapy and who had premenopausal estradiol levels despite chemotherapy, ovarian suppression in addition to tamoxifen reduced the risk of breast cancer recurrence compared to tamoxifen alone.

The results of previous studies indicate that the addition of ovarian suppression to tamoxifen is not an appropriate routine treatment option for all premenopausal patients with hormone-responsive breast cancer. Instead, only premenopausal patients with hormone-responsive breast cancer who would benefit the most from ovarian suppression in addition to tamoxifen should be selected. In this group of patients, the efficacy of GnRH agonist is similar to that of chemotherapy as reported in previous studies, and further replaces chemotherapy as an alternative. As in the current study, premenopausal patients with T1-T2, hormone-responsive, HER2-negative breast cancer might be good candidates. We found no statistically significant difference in RFS and CSS between our GnRHa+T and AC-\>T groups in premenopausal patients with hormone-responsive, early breast cancer. However, a large-scale, randomized controlled study is still required for prospective comparison of the efficacies of GnRHa+T and AC-\>T.

As described above, only 68 of our 994 patients showed recurrence, with a 5-year RFS of 95.9%; there were 15 cancer-specific deaths with a 5-year CSS of 98.9% and 25 overall deaths with a 5-year OS of 98.3%. In designing a randomized controlled study for separate statistical confirmation of the presence of non-inferiority within 1%, 3%, and 5% margins, total sample sizes of 4,561, 1,650, and 964, respectively, would be required for RFS, with sizes of 2,423, 1,370, and 1,019 for CSS. Therefore, a long accrual time as well as multicenter collaboration would be required to prospectively confirm the equivalence, non-inferiority, or superiority of GnRHa+T versus AC-\>T. Until these prospective data are obtained, large-scale retrospective data might provide valuable information on effective treatments in this specific group of patients. To the best of our knowledge, the current study included the largest series of retrospective data comparing GnRHa+T to AC-\>T in premenopausal patients with hormone-responsive, T1-T2, N0 breast cancer.

The optimal treatment duration of GnRH agonist is also controversial. In the current study, patients who chose GnRHa+T treatment received GnRH agonist for 2 years. Shiba et al. \[[@b17-crt-2015-444]\] reported that adjuvant leuprorelin treatment for 3 or more years with tamoxifen showed a survival benefit and safety profile similar to that for 2 years in premenopausal patients with endocrine-responsive breast cancer in a randomized controlled study. Similar to our results, several trials using GnRH agonists for 2 years reported no differences in treatment outcomes between GnRH agonists and chemotherapy \[[@b6-crt-2015-444],[@b13-crt-2015-444],[@b16-crt-2015-444],[@b18-crt-2015-444]\]. On the other hand, trials showing a superiority of hormonal blockade over chemotherapy used GnRH agonists for 2 or 3 years combined with tamoxifen for 5 years or tamoxifen with ovarian ablation \[[@b19-crt-2015-444],[@b20-crt-2015-444]\]. The patients included in SOFT \[[@b3-crt-2015-444]\] had completed 5 years of ovarian suppression. The treatment duration is an important issue since the duration of GnRH-agonist treatment determines the duration of amenorrhea. Swain et al. \[[@b21-crt-2015-444]\] proposed that a longer duration of amenorrhea was associated with improved survival regardless of the chemotherapy regimen and estrogen receptor status. In accordance with these findings, one of the groups in SOFT \[[@b3-crt-2015-444]\] in which a survival benefit was found by addition of ovarian suppression to tamoxifen comprised patients with premenopausal estradiol levels despite chemotherapy, with ovarian suppression in addition to tamoxifen reducing the risk of breast cancer recurrence compared to tamoxifen alone. This finding implies that the duration of amenorrhea is an important prognostic factor regardless of the type of adjuvant therapy. In their meta-analysis, the Early Breast Cancer Overview group \[[@b22-crt-2015-444],[@b23-crt-2015-444]\] concluded that GnRH agonists showed an additional benefit when administered after chemotherapy, either alone or with tamoxifen, in women aged 40 years or younger, in whom chemotherapy is less likely to induce permanent amenorrhea than in older women. Several studies have reported significant improvements in relapse and survival in premenopausal women with breast cancer who develop amenorrhea after chemotherapy compared with those who did not \[[@b24-crt-2015-444],[@b25-crt-2015-444]\]. In the current study, in the subset of patients younger than 39 years, the 5-year CSS and OS rates appeared to be better in the GnRHa+T group than in the AC-\>T group. Therefore, future research should confirm the optimal duration of GnRH-agonist treatment and whether maintaining amenorrhea for a longer period can provide a survival benefit.

The limitation of this study is the retrospective nature. The clinical and tumor characteristics of the two treatment groups are not evenly distributed. Therefore, results of direct comparison between two treatment groups might be uncertain. PS matching and inverse probability weighting was applied to overcome this limitation to minimize the heterogeneity of the treatment group.

Conclusion
==========

In conclusion, the findings of this study suggest that GnRHa+T is a comparable alternative to AC-\>T in premenopausal patients with hormone-responsive, HER2-negative, N0, T1-T2 breast cancer.
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###### 

Characteristics of the overall and the propensity-matched cohorts

  Variable                    Overall cohorts   Propensity-matched cohort                                        
  --------------------------- ----------------- --------------------------- ---------- ------------ ------------ ----------
  **Age (yr)**                44.79±4.9         42.52±6.69                  \< 0.001   43.83±5.37   43.47±6.18   0.466
  **Operation method**                                                                                           
   BCS                        462 (76)          217 (56.2)                  \< 0.001   172 (66.2)   167 (64.2)   0.622
   Mastectomy                 146 (24)          168 (43.5)                             88 (33.9)    93 (35.8)    
  **Nuclear grade**                                                                                              
   1                          59 (10.1)         33 (9.1)                    \< 0.001   21 (8.6)     21 (8.5)     0.994
   2                          448 (76.5)        241 (66.2)                             179 (73.4)   181 (73.6)   
   3                          79 (13.5)         90 (24.7)                              44 (18)      44 (17.9)    
  **Histologic grade**                                                                                           
   1                          72 (12.4)         36 (9.8)                    \< 0.002   26 (10.6)    27 (11)      0.726
   2                          431 (74.2)        249 (67.5)                             178 (72.7)   174 (70.7)   
   3                          78 (13.4)         84 (22.8)                              41 (16.7)    45 (18.3)    
  **Estrogen receptor**                                                                                          
   +                          573 (94.2)        334 (86.5)                  \< 0.001   239 (91.9)   241 (92.7)   0.723
   --                         35 (5.8)          52 (13.5)                              21 (8)       19 (7.3)     
  **Progesterone receptor**                                                                                      
   +                          561 (92.3)        333 (86.3)                  0.002      233 (89.6)   231 (88.9)   0.781
   --                         47 (7.7)          53 (13.7)                              27 (10.4)    29 (11.2)    
  **Tumor stage**                                                                                                
   T1a+T1b                    97 (16)           18 (4.7)                    \< 0.001   29 (11.2)    18 (6.9)     0.241
   T1c                        396 (65.1)        163 (42.2)                             135 (51.9)   140 (53.8)   
   T2                         115 (18.9)        205 (53.1)                             96 (36.9)    102 (39.2)   
  **HER2**                                                                                                       
   --                         312 (51.3)        202 (52.3)                  \< 0.896   128 (49.2)   137 (52.7)   0.448
   +                          296 (48.7)        184 (47.7)                             132 (50.8)   123 (47.3)   
  **p53**                                                                                                        
   --                         430 (84.8)        253 (71.9)                  \< 0.001   195 (75)     195 (75)     \> 0.999
   +                          77 (15.2)         99 (28.1)                              65 (25)      65 (25)      

Values are presented as mean±standard deviation or number (%). GnRHa+T, combined gonadotropin-releasing hormone agonist and tamoxifen; AC-\>T, sequential adriamycin and cyclophosphamide chemotherapy and tamoxifen; BCS, breast-conserving surgery.

p-values are based on the paired t test for continuous variables and on McNemar's test for categorical variables.

###### 

HRs for clinical outcomes among overall, T1a+T1b group, T1c group, T2 group, and the propensity-matched patients

  Parameter                       Treatment   DF   HR      95% CI        p-value
  ------------------------------- ----------- ---- ------- ------------- ---------
  **Overall cohort**                                                     
   RFS                            GnRHa+T     1    0.791   0.488-1.282   0.342
                                  AC-\>T           1                     
   CSS                            GnRHa+T     1    0.249   0.079-0.788   0.018
                                  AC-\>T           1                     
   OS                             GnRHa+T     1    0.377   0.166-0.857   0.020
                                  AC-\>T           1                     
  **T1a+T1b group**                                                      
   RFS                            GnRHa+T     1    0.299   0.071-1.256   0.099
                                  AC-\>T           1                     
   OS                             GnRHa+T     1    0.180   0.011-2.884   0.226
                                  AC-\>T           1                     
  **T1c group**                                                          
   RFS                            GnRHa+T     1    1.090   0.479-2.478   0.838
                                  AC-\>T           1                     
   CSS                            GnRHa+T     1    0.405   0.082-2.006   0.268
                                  AC-\>T           1                     
   OS                             GnRHa+T     1    0.480   0.143-1.164   0.094
                                  AC-\>T           1                     
  **T2 group**                                                           
   RFS                            GnRHa+T     1    1.090   0.519-2.290   0.820
                                  AC-\>T           1                     
   CSS                            GnRHa+T     1    0.280   0.034-2.294   0.235
                                  AC-\>T           1                     
   OS                             GnRHa+T     1    0.280   0.034-2.294   0.235
                                  AC-\>T           1                     
  **Propensity-matched cohort**                                          
   RFS                            GnRHa+T     1    1.461   0.707-3.021   0.306
                                  AC-\>T           1                     
   CSS                            GnRHa+T     1    0.247   0.028-2.223   0.212
                                  AC-\>T           1                     
   OS                             GnRHa+T     1    0.333   0.089-1.243   0.102
                                  AC-\>T           1                     

HR, hazard ratio; DF, degree of freedom; CI, confidence interval; RFS, recurrence-free survival; GnRHa+T, combined gonadotropin-releasing hormone agonist and tamoxifen; AC-\>T, sequential adriamycin and cyclophosphamide chemotherapy and tamoxifen; CSS, cancer-specific survival; OS, overall survival.

###### 

HRs for clinical outcomes using inverse probability of weighting among the propensity-matched patients

  Parameter   Treatment   DF   HR      95% CI        p-value
  ----------- ----------- ---- ------- ------------- ---------
  RFS         GnRHa+T     1    1.196   0.692-2.066   0.522
              AC-\>T           1                     
  CSS         GnRHa+T     1    0.377   0.099-1.442   0.154
              AC-\>T           1                     
  OS          GnRHa+T     1    0.333   0.131-0.846   0.021
              AC-\>T           1                     

Trimming (by 0.1, \> 10) does not affect the data. HR, hazard ratio; DF, degree of freedom; CI, confidence interval; RFS, recurrence-free survival; GnRHa+T, combined gonadotropin-releasing hormone agonist and tamoxifen; AC-\>T, sequential adriamycin and cyclophosphamide chemotherapy and tamoxifen; CSS, cancer-specific survival; OS, overall survival.
